A Pilot Proteomic Analysis of Salivary Biomarkers in Autism Spectrum Disorder.
A small pilot shows saliva proteins can flag autism-related biology, nudging us toward faster, cheaper screening tools.
01Research in Context
What this study did
Little et al. (2015) compared spit samples from people with autism and neurotypical peers.
They used mass spectrometry to spot proteins that differed between the two groups.
The team wanted to know if saliva could give us quick, painless biomarkers for ASD.
What they found
Several immune and gut-linked proteins showed up in different amounts.
The results say saliva tests can flag biological differences tied to autism.
It was a small pilot, but the pattern was clear enough to warrant bigger studies.
How this fits with other research
Fusaroli et al. (2022) pooled voice data and also found small, reliable differences between autistic and typical speakers.
Both papers agree: no single marker is perfect, but biology keeps showing group patterns.
Klin (2025) goes further, arguing FDA-cleared eye-tracking tools could diagnose toddlers today.
Together the work forms a timeline: 2015 proves spit is worth a look, 2022 shows voice adds clues, 2025 says eye-tracking is ready for clinics.
Why it matters
You can’t run mass spec in your clinic, but you can watch for new saliva-based screening kits.
Until then, keep using standard tools, yet stay open to biological add-ons that may speed referral and tailor supports.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Sign up for alerts on saliva-based ASD tests so you can pilot them when they hit the market.
02At a glance
03Original abstract
Autism spectrum disorder (ASD) prevalence is increasing, with current estimates at 1/68-1/50 individuals diagnosed with an ASD. Diagnosis is based on behavioral assessments. Early diagnosis and intervention is known to greatly improve functional outcomes in people with ASD. Diagnosis, treatment monitoring and prognosis of ASD symptoms could be facilitated with biomarkers to complement behavioral assessments. Mass spectrometry (MS) based proteomics may help reveal biomarkers for ASD. In this pilot study, we have analyzed the salivary proteome in individuals with ASD compared to neurotypical control subjects, using MS-based proteomics. Our goal is to optimize methods for salivary proteomic biomarker discovery and to identify initial putative biomarkers in people with ASDs. The salivary proteome is virtually unstudied in ASD, and saliva could provide an easily accessible biomaterial for analysis. Using nano liquid chromatography-tandem mass spectrometry, we found statistically significant differences in several salivary proteins, including elevated prolactin-inducible protein, lactotransferrin, Ig kappa chain C region, Ig gamma-1 chain C region, Ig lambda-2 chain C regions, neutrophil elastase, polymeric immunoglobulin receptor and deleted in malignant brain tumors 1. Our results indicate that this is an effective method for identification of salivary protein biomarkers, support the concept that immune system and gastrointestinal disturbances may be present in individuals with ASDs and point toward the need for larger studies in behaviorally-characterized individuals.
Autism research : official journal of the International Society for Autism Research, 2015 · doi:10.1002/aur.1450